Should a person preconditioned to blood clots fly?

By SWA

Whether a person preconditioned to blood clots, also known as thrombosis, should fly depends on several factors, including the severity of their condition, the location and stability of the clot, and their overall health. It's important for individuals with a history of blood clots or those currently experiencing them to consult with a healthcare provider before flying. Here are some considerations:

  1. Risk of Deep Vein Thrombosis (DVT) in Flights: Long flights can increase the risk of deep vein thrombosis (DVT), where blood clots form in the deep veins of the legs. This risk is due to prolonged immobility, which can slow down blood circulation.

  2. Current State of Clots: If a person currently has an unstable blood clot, flying might not be recommended. The changes in pressure and the prolonged immobility associated with air travel can increase the risk of a clot dislodging and leading to a pulmonary embolism, which is a medical emergency.

  3. Stability and Treatment: If a person is on anticoagulation therapy (blood thinners) and their condition is stable, flying may be safer. However, the decision should be made in consultation with a healthcare provider.

  4. Duration of the Flight: Longer flights pose a greater risk due to extended periods of immobility. For shorter flights, the risk might be less, but individual risk factors still need to be considered.

  5. Preventative Measures: If cleared to fly, individuals with a history of blood clots are often advised to take certain precautions, such as wearing compression stockings, staying hydrated, avoiding alcohol and sedatives, and walking or stretching periodically during the flight.

  6. Medical Clearance: In some cases, medical clearance from a healthcare provider might be necessary. This is especially true if the individual has recently had a clot or is undergoing treatment for clots.

  7. Travel Insurance: It's also advisable to consider travel insurance that covers medical emergencies, especially for those with known health risks.

In summary, the decision for a person with blood clots to fly should be made on a case-by-case basis in consultation with a healthcare provider, taking into account the individual's health status, the stability of the clot, and the specifics of the travel plan.

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more